Kidney damage biomarkers: Novel tools for the diagnostic assessment of acute kidney injury in cirrhosis
Potential conflict of interest: Dr. Murray consults for and is on the speakers' bureau for Abbott. He consults for Astellas and AM Pharma. He advises EKF Diagnostics and FAST Diagnostics.
Dr. Murray's AKI biomarker research was supported by the Health Research Board (Ireland; grant HRA_POR 2011 128).
See Article on Page 622
No abstract is available for this article.